莱沃西门丹:治疗儿科心力衰竭的疗效和安全性
Mehmet Akif Dündar1, Mustafa Yılmaz2, Mustafa Argun3
1Health Sciences University, Kayseri City Training and Research Hospital, Department of Pediatrics, Division of Pediatric Intensive Care - Kayseri, Turkey.
Revista da Associacao Medica Brasileira (1992)
|July 24, 2024
概括
莱沃西门丹在儿童心力衰竭患者中改善了心血管稳定性,这些患者对标准治疗没有反应. 这项研究强调了其安全性和有效性,提高了心脏结果,减少了对其他内类药物的需求.
科学领域:
- 儿童心脏病学 儿童心脏病学
- 心血管药理学心血管药理学
- 临界护理医学 临界护理医学
背景情况:
- 儿科心力衰竭 (DHF) 通常需要先进的血液动力学支持.
- 传统的内类药物可能不足或与儿科DHF的不良影响有关.
- 莱沃西门丹提供了一种新的方法来支持具有独特的作用机制的内.
研究的目的:
- 评估levosimendan在患有大发性炎症的儿科患者中的有效性和安全性.
- 评估levosimendan在改善心血管稳定的作用.
- 确定levosimendan是否可以减少对常规无otropic 药物的需求.
主要方法:
- 一组由15名患有大发性血的儿科患者组成的队列接受了levosimendan.
- 患者患有急性发性心肌炎或先天性心脏病后手术并发症的二次性DHF.
- 在levosimendan输液期间,对心血管参数,不良事件和并发药物使用进行了监测.
主要成果:
- 在24小时内,Levosimendan显著改善了左心室喷射率 (LVEF),从45%提高到58% (p<0.001).
- 观察到压缩性和压缩性血压的显著增加以及心率的下降.
- 乳酸盐水平在6小时内显著下降 (p<0.001),表明组织输液得到改善.
结论:
- 莱沃西门丹对于患有常规异型药物耐火性DHF的儿科患者是有效和安全的.
- 它增强了心血管稳定,并改善了关键的血液动力学参数.
- 莱沃西门丹代表了儿科心力衰竭的宝贵治疗选择,有可能减少对传统异能药物的依赖.
相关概念视频
01:26Heart Failure Drugs: Inotropic Agents
559
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
559
01:22Heart Failure Drugs: β-Blockers
333
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
333
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
414
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
414
01:22Heart Failure Drugs: Diuretics
356
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
356